Table 1.

Demographics of cord blood and bone marrow recipients that contributed to the T-cell reconstitution study

CBT (n = 30; 26 single-cord and 4 double-cord)BMT (n = 40)
Age at transplant
 1 y (0.1-12)4.3 y (0.6-12)
Diagnosis
 Acute leukemia, 12 (40%); myelodysplastic syndrome/chronic myeloid leukemia, 2 (6%); immunodeficiency, 12 (40%); hemophagocytic lymphohistiocytosis 4 (14%)Acute leukemia, 17 (42%); myelodysplastic syndrome/chronic myeloid leukemia, 3 (8%); immunodeficiency, 13 (32%); hemophagocytic lymphohistiocytosis, 5 (13%); metabolic, 2 (5%)
Conditioning
 Myeloablative conditioning, 29 (97%; TBI or Bu-based or treosulfan-based); no conditioning, 1 (3%)Myeloablative conditioning, 40 (100%; TBI or Bu-based or treosulfan-based)
HLA matching
 ≤8/10: 1710/10: 40
 9/10: 14
 10/10: 03
Acute GVHD
 Grade II: 10 (33%)Grade II: 7 (18%)
 Grade III-IV: 5 (16%)Grade III-IV: 3 (8%)
Viral reactivations
 CMV: 4 (13%)CMV: 7 (17%)
 ADV: 4 (13%)ADV: 4 (10%)